Nano-hydroxyapatite vs fluoride: what the evidence actually says about remineralization

A 2025 meta-analysis set out to answer the question directly: four randomized controlled trials, head-to-head, nano-hydroxyapatite versus fluoride, cavity progression as the endpoint. The result: RR 0.98, p=0.61. No statistically significant difference. In either direction.

That result is easy to misread. Nano-HAP advocates will say "not inferior means it's just as good — so why use fluoride?" Skeptics will counter: "four trials vs over a hundred for fluoride — the evidence gap is real." Both miss the point. Here's what the data actually shows.

The 2025 meta-analysis: what it found and what it didn't

Pawinska et al., published in the Journal of Dentistry (PubMed ID 40107597), pooled four RCTs comparing nano-hydroxyapatite directly against fluoride toothpaste on caries progression.

The numbers:

• Relative Risk of caries progression: RR 0.98 (95% CI 0.71–1.34), p=0.61
• Odds Ratio: OR 0.90 (95% CI 0.56–1.44), p=0.68

Both confidence intervals cross 1.0. Both p-values are far from significance. The authors' conclusion, verbatim: "HAP could be an effective alternative to fluoride."

Not superior. Not inferior. Comparable.

A separate in situ RCT from 2019 (PMC6901576, n=30) compared 10% nano-HAP paste against 500 ppm fluoride on remineralization of primary tooth enamel. Result: 55.8% vs 56.9%, p=0.81. Statistically identical.

One caveat worth keeping: the 500 ppm fluoride comparator in that 2019 trial is a children's concentration — not the adult standard of 1450 ppm. That limits how far the equivalence claim extends for adults specifically, even if the general picture holds.

Sensitivity: where nano-HAP actually outperforms

This is where the clearest data lives.

A meta-analysis of 44 clinical trials (PMC9844412, Biomimetics, 2023) looked specifically at dentinal hypersensitivity. Nano-HAP versus placebo: −39.5% pain reduction on the Schiff scale. Nano-HAP versus fluoride in direct comparison: −23% in favor of nano-HAP.

Nano-HAP outperforms fluoride on sensitivity — not because it's a stronger molecule, but because it works through a mechanism fluoride simply doesn't have.

The mechanism is straightforward. Nanoparticles around 20 nm in size physically block the dentinal tubules — the open microtubules through which stimuli (cold, acid, pressure) travel to the pulp. Fluoride manages the chemistry of mineral exchange. It doesn't plug the tube.

Supporting data: a 90-day RCT (PMC9317292) found 18% Zn-HAP paste reduced the Schiff sensitivity index from 1.75 to 0.40 — an outcome the fluoride control group did not reach. An 8-week RCT of 85 patients (PMC8233401) showed 10–15% nano-HAP performing on par with the NovaMin/Sensodyne sensitivity benchmark (P less than 0.001).

Why particle size is the actual mechanism

Not all hydroxyapatite works the same way — and this is not a marketing distinction.

Native hydroxyapatite crystals in enamel measure around 20 nm. Synthetic nano-HAP in the same size range (20–50 nm) can physically enter subsurface enamel defects, adsorb onto the crystal lattice, and occlude dentinal tubules. Micro-HAP particles at 1–5 micrometers stay on the surface. The depth of penetration is different. The biological outcome is different.

The working range for clinical effect: 20–100 nm. This is a physics requirement, not a regulatory one.

On industry ties: the honest caveat

The nano-HAP evidence base is growing — but context matters.

Several of the most-cited meta-analyses carry industry affiliations: Enax and Meyer are linked to Dr. Kurt Wolff GmbH (manufacturer of Biorepair), and portions of the research trace back to Sangi Co., the Japanese company that pioneered HAP toothpaste in the 1980s. Industry funding doesn't automatically invalidate data, but it does affect how much weight the findings should carry on their own.

The important point: the direction of results holds up in independent work too. The in situ RCT by Ismail et al. (PMC6901576) — a university study without apparent commercial ties — lands in the same place: non-inferiority to fluoride on remineralization. The sensitivity advantage appears across trials from different groups.

Safety: why this matters for families

Nano-HAP is a biomimetic. It's a synthetic form of the mineral enamel is already made of. When swallowed, it metabolizes as calcium and phosphate — normal dietary components.

That makes nano-HAP the only remineralizing agent with real clinical evidence where ingestion is not a clinical concern. This is relevant for children under 6: they can't reliably spit, and dental fluorosis — a permanent enamel defect from chronic fluoride excess during tooth development — is a real risk when dose control is imperfect.

Fluoride in children's toothpaste (1000 ppm) is well-studied and safe when used in the right amounts (a rice-sized smear under age 3). Nano-HAP removes the need for that level of dose control. That's a different risk profile for a specific situation — not a universal "better."

What this means in practice

Nano-HAP does not defeat fluoride. But it matches it where it matters most — cavity prevention — and surpasses it where fluoride has no mechanism at all: reducing dentinal sensitivity through physical tubule occlusion.

Practical framing:

• Sensitive teeth, exposed root surfaces, gum recession — nano-HAP is the first choice.
• Children under 6 — nano-HAP eliminates fluorosis risk from accidental swallowing.
• Healthy adults with low caries risk — nano-HAP is a clinically supported fluoride alternative.
• High caries risk, poor hygiene, orthodontic treatment — fluoride 1450 ppm, with the broader evidence base behind it.

The choice is not between a good ingredient and a bad one. It's between two mechanisms — each appropriate in different situations.

---

Sources: Pawinska M et al. J Dent. 2025. PubMed 40107597 · Enax J et al. Biomimetics. 2023. PMC9844412 · Ismail FA et al. BDJ Open. 2019. PMC6901576 · Zhu M et al. Clin Oral Investig. 2022. PMC9317292 · Vano M et al. Sci Rep. 2021. PMC8233401 · MDPI J Funct Biomater. 2025. doi:10.3390/jfb16090325